A PSMA-based PET scan can change SRT decisions

The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …

Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

Axumin PET/CT scans change treatment recommendations in recurrent prostate cancer

The value of many cancer-related tests is actually based on whether the results of the particular test change the way that  physicians plan to treat specific patients (hopefully for the better). … READ MORE …

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …

Yet another new PMSA-linked radioisotope enters clinical trials in prostate cancer

As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …

Increasing availability of the Axumin-enhanced PET scan

Back in May this year we reported that the US Food and Drug Administration had approved a new type of imaging agent known as [18F]fluciclovine (Axumin®) for use in association with PET scans in men with recurrent prostate cancer that might have spread to other parts of the body, but which was not evident on older forms of scan. … READ MORE …

Can PSMA PET scans replace the need for bone and CT scans?

A new review article suggests the possibility that radiolabeled prostate specific membrane antigens (PSMAs) and PET scans may, at some point in the not too distant future, replace bone and CT scans in diagnosis and monitoring of men with advanced forms of prostate cancer. … READ MORE …